Solana Co
For the period ended Dec 31, 2024. Filed Mar 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 25, 2025
HSDT$1.83-4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended | ||||||
| · · December 31, | ||||||
| | 2024 | 2023 | ||||
| | | | | | | |
| Cash flows from operating activities: · · | ||||||
| Net loss | | $(11,742) | | $(8,850) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | ||||
| Change in fair value of derivative liability | | (2,981) | | (2,966) | ||
| Stock-based compensation expense | | 2,522 | | 1,629 | ||
| Foreign exchange loss (gain) | | 999 | | (286) | ||
| Depreciation expense | | 36 | | 45 | ||
| Amortization expense | | 24 | | 117 | ||
| Fixed asset impairment | | 40 | | | 159 | |
| Provision for (reversal of) inventory reserve | | 28 | | (5) | ||
| Non-cash operating lease expense | | 41 | | 52 | ||
| Changes in operating assets and liabilities: | | | | |||
| Accounts receivable | | 41 | | (44) | ||
| Other receivables | | (46) | | (247) | ||
| Inventory | | (607) | | 137 | ||
| Prepaid expense and other current assets | | 364 | | 54 | ||
| Operating lease liabilities | | (45) | | (53) | ||
| Accounts payable | | 344 | | (103) | ||
| Accrued and other current liabilities | | (18) | | (20) | ||
| Deferred revenue | | (41) | | (35) | ||
| Net cash used in operating activities | | (11,041) | | (10,416) | ||
| Cash flows from investing activities: | | | ||||
| Purchase of property and equipment | | (5) | | (29) | ||
| Net cash used in investing activities | | (5) | | (29) | ||
| Cash flows from financing activities: | | | ||||
| Proceeds from issuance of common stock | | 2,961 | | 500 | ||
| Proceeds from issuance of warrants | | | 4,829 | | | — |
| Proceeds from exercise of warrants | | | 164 | | | 642 |
| Share issuance costs | | (1,000) | | (65) | ||
| Net cash provided by financing activities | | 6,954 | | 1,077 | ||
| Effect of currency exchange rate changes on cash and cash equivalents | | (2) | | 1 | ||
| Net decrease in cash and cash equivalents | | (4,094) | | (9,367) | ||
| Cash and cash equivalents at beginning of period | | 5,182 | | 14,549 | ||
| Cash and cash equivalents at end of period | | $1,088 | | $5,182 | ||
| Supplemental cash flow information | | | ||||
| Non-cash investing and financing transactions: | | | | | ||
| Derivative warrant liability reclassified to equity on exercise of warrants | | $101 | | $628 | ||
| Deferred offering costs reclassified to equity upon public offering | | $132 | | $— | ||
Helius Medical Technologies, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.